BATS BZX Real-Time Price
As of 3:39pm ET
| +0.025 / +0.32%|
The 3 analysts offering 12-month price forecasts for Melinta Therapeutics, Inc. have a median target of 10.00, with a high estimate of 21.00 and a low estimate of 8.00. The median estimate represents a +26.18% increase from the last price of 7.93.
The current consensus among 4 polled investment analysts is to Hold stock in Melinta Therapeutics, Inc.. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.